Corium International Inc. (NASDAQ:CORI) shares traded up 7.5% during trading on Tuesday . The stock traded as high as $4.79 and last traded at $4.73, with a volume of 170,139 shares traded. The stock had previously closed at $4.40.

Several research analysts recently commented on the stock. FBR & Co reiterated a “buy” rating on shares of Corium International in a report on Monday, May 2nd. Zacks Investment Research upgraded shares of Corium International from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Tuesday, July 19th. Jefferies Group reiterated a “buy” rating and issued a $9.00 target price on shares of Corium International in a report on Wednesday, May 11th. WBB Securities upgraded shares of Corium International from a “hold” rating to a “speculative buy” rating and set a $11.00 price objective on the stock in a report on Tuesday, May 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $15.00 price objective on shares of Corium International in a report on Thursday, June 23rd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Corium International presently has an average rating of “Buy” and a consensus target price of $11.92.

The firm’s market cap is $105.42 million. The firm’s 50 day moving average is $4.24 and its 200 day moving average is $4.35.

Corium International (NASDAQ:CORI) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.08. Equities research analysts anticipate that Corium International Inc. will post ($1.63) earnings per share for the current year.

In other Corium International news, Director Eric Bjerkholt bought 24,500 shares of Corium International stock in a transaction that occurred on Thursday, May 19th. The stock was acquired at an average price of $3.64 per share, for a total transaction of $89,180.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.